AIM ImmunoTech Announces That Analysis Of AMP-518 Complete Clinical Patient Data Underscores Ampligen's Potential To Improve The Post-COVID Condition Of Fatigue, And That This Would Be The Likely Subject Population For AIM's Planned Follow-up Clinical...
AIM ImmunoTech Announces That Analysis Of AMP-518 Complete Clinical Patient Data Underscores Ampligen's Potential To Improve The Post-COVID Condition Of Fatigue, And That This Would Be The Likely Subject Population For AIM's Planned Follow-up Clinical...
aim immunotech宣布对AMP-518完整的临床患者数据进行分析，强调Ampligen改善后COVID疲劳症状的潜力，并表示这将是AIM计划中后续临床研究的研究对象群体。
AIM ImmunoTech Announces That Analysis Of AMP-518 Complete Clinical Patient Data Underscores Ampligen's Potential To Improve The Post-COVID Condition Of Fatigue, And That This Would Be The Likely Subject Population For AIM's Planned Follow-up Clinical Trial
AiM ImmunoTech 宣布，对 AMP-518 完整临床患者数据的分析凸显了 Ampligen 改善后疲劳状况的潜力，这将是 AIM 计划中的后续临床试验的受试者群体
AIM ImmunoTech Inc. (NYSE:AIM) ("AIM") today announced that an analysis of the complete clinical patient data from the AMP-518 clinical trial supported the Company's belief in Ampligen as a potential therapeutic for people with the moderate-to-severe Post-COVID condition of fatigue, and that this would be the likely subject population for AIM's planned follow-up clinical trial.
AiM ImmunoTech Inc.（纽约证券交易所代码：AIM）（“AIM”）今天宣布，对来自 AMP-518 临床试验的完整临床患者数据的分析支持了该公司的信念，即Ampligen是COVID后中度至重度疲劳症状患者的潜在治疗药物，这将是AIM计划的后续临床试验的受试者群体。
资讯热榜
更新时间